Mayo Clinic Phage Program Biobank

• Conditions: Bacteriophage Therapy

• Registration Number: NCT05314426
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this study is to help scientists and clinicians discover answers to research questions related to antibiotic-resistant bacterial infections, and the role that phage therapy plays as a possible treatment.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-03-30
• Study First Submitted QC: 2022-03-30
• Study First Posted: 2022-04-06
• Study Start: 2022-04-19
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-05
• Last Update Posted: 2024-06-06
• Primary Completion: 2027-04
• Study Completion: 2027-04

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• ≥ 18 years of age.
• Able to provide informed consent.
• Individual must have a future treatment plan to receive or has historically received phage therapy.

Read More

Exclusion Criteria

• Individuals , 18 years of age.
• Unwilling/unable to provide informed consent.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Enrollment of study participants	5 years	To recruit and enroll participants up to 100 participants who have received or will receive phage therapy treatment
Medical record review	5 years	Review the medical record of enrolled participants to ascertain any new health outcomes.
Collection of biospecimens	5 years	Total number of biospecimens collected which may include blood samples and synovial fluid
Increase treatment options and level of care for patients with bacterial infections	5 years	Total number of collaborations with clinical investigators and researchers at both Mayo Clinic and across the globe.

Trial Locations

Locations (1)

Mayo Clinic Rochester; 🇺🇸 Rochester, Minnesota, United States